-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Mersana Therapeutics (NASDAQ:MRSN) Trading Up 3.7%
Mersana Therapeutics (NASDAQ:MRSN) Trading Up 3.7%
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s stock price was up 3.7% during mid-day trading on Friday . The company traded as high as $6.66 and last traded at $6.66. Approximately 2,607 shares traded hands during trading, a decline of 100% from the average daily volume of 1,150,149 shares. The stock had previously closed at $6.42.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on MRSN shares. Wedbush reiterated an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. SVB Leerink increased their target price on Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th. Finally, Robert W. Baird increased their target price on Mersana Therapeutics from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.
Get Mersana Therapeutics alerts:Mersana Therapeutics Stock Up 5.3 %
The stock has a market capitalization of $656.87 million, a price-to-earnings ratio of -2.76 and a beta of 1.75. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.18. The business's 50-day moving average is $6.88 and its two-hundred day moving average is $5.05.
Mersana Therapeutics (NASDAQ:MRSN – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.05). Mersana Therapeutics had a negative net margin of 3,057.88% and a negative return on equity of 140.57%. The business had revenue of $4.28 million for the quarter, compared to analysts' expectations of $3.18 million. Equities analysts anticipate that Mersana Therapeutics, Inc. will post -1.69 EPS for the current year.Institutional Trading of Mersana Therapeutics
Large investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new position in shares of Mersana Therapeutics during the 1st quarter worth $36,000. Quantbot Technologies LP purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $37,000. Washington University purchased a new position in Mersana Therapeutics during the 2nd quarter valued at about $43,000. Virtu Financial LLC purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $53,000. Finally, Point72 Hong Kong Ltd purchased a new position in Mersana Therapeutics during the 4th quarter valued at about $57,000. Hedge funds and other institutional investors own 95.12% of the company's stock.
About Mersana Therapeutics
(Get Rating)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Further Reading
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s stock price was up 3.7% during mid-day trading on Friday . The company traded as high as $6.66 and last traded at $6.66. Approximately 2,607 shares traded hands during trading, a decline of 100% from the average daily volume of 1,150,149 shares. The stock had previously closed at $6.42.
默萨纳治疗公司(纳斯达克代码：MRSN-GET Rating)周五午盘股价上涨3.7%，最高报6.66美元。全天约有2,607股股票易手，较平均日成交量1,150,149股下跌100%。此前该股收盘价为6.42美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of research analysts have recently issued reports on MRSN shares. Wedbush reiterated an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. SVB Leerink increased their target price on Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th. Finally, Robert W. Baird increased their target price on Mersana Therapeutics from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.
一些研究分析师最近发布了关于MRSN股票的报告。韦德布什在8月9日星期二的一份研究报告中重申了对Mersana治疗公司股票的“跑赢大盘”评级。SVB Leerink在8月9日周二的一份研究报告中将Mersana Treateutics的目标价从13.00美元上调至14.00美元，并给予该公司“跑赢大盘”的评级。最后，Robert W.Baird在8月9日星期二的一份研究报告中将Mersana Treeutics的目标价从18.00美元上调至20.00美元，并给予该公司“跑赢大盘”的评级。
Mersana Therapeutics Stock Up 5.3 %
Mersana治疗公司股价上涨5.3%
The stock has a market capitalization of $656.87 million, a price-to-earnings ratio of -2.76 and a beta of 1.75. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.18. The business's 50-day moving average is $6.88 and its two-hundred day moving average is $5.05.
该股市值为6.5687亿美元，市盈率为-2.76倍，贝塔系数为1.75。该公司的速动比率为3.32，流动比率为3.32，债务权益比为0.18。该业务的50日移动均线切入位在6.88美元，200日移动均线切入位在5.05美元。
Institutional Trading of Mersana Therapeutics
Mersana治疗公司的机构交易
Large investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new position in shares of Mersana Therapeutics during the 1st quarter worth $36,000. Quantbot Technologies LP purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $37,000. Washington University purchased a new position in Mersana Therapeutics during the 2nd quarter valued at about $43,000. Virtu Financial LLC purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $53,000. Finally, Point72 Hong Kong Ltd purchased a new position in Mersana Therapeutics during the 4th quarter valued at about $57,000. Hedge funds and other institutional investors own 95.12% of the company's stock.
大型投资者最近买卖了该公司的股票。胜利资本管理公司在第一季度购买了价值3.6万美元的Mersana治疗公司的新股票头寸。Quantbot Technologies LP在第一季度购买了Mersana治疗公司的一个新头寸，价值约3.7万美元。华盛顿大学在第二季度购买了Mersana治疗公司的一个新头寸，价值约43,000美元。Virtu Financial LLC在第一季度购买了Mersana Treeutics的一个新头寸，价值约53,000美元。最后，Point72 Hong Kong Ltd在第四季度购买了Mersana Treeutics的新头寸，价值约57,000美元。对冲基金和其他机构投资者持有该公司95.12%的股票。
About Mersana Therapeutics
关于Mersana Treeutics
(Get Rating)
(获取评级)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Mersana治疗公司是一家临床阶段生物制药公司，为未得到满足需求的癌症患者开发抗体药物结合物(ADC)。它开发了XMT-1592，一种针对NaPi2b表达肿瘤细胞的Dolasynten ADC，正在进行治疗卵巢癌和NSCLC腺癌的I期临床试验。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
- 免费获取StockNews.com关于Mersana治疗公司(MRSN)的研究报告
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 雷神工业走出谷底
- 利润下降对CarMax价值主张的挑战
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Mersana治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Mersana Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧